Company
Allergy Therapeutics PLC
LON:AGY
Allergy Therapeutics PLC is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
298 stories · page 3 of 15
Archive
Small Cap Feast - Allergy Therapeutics, Crossword Cybersecurity, and more...
19 April 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners: No joiners today.Leavers: No leavers today.What’s cooking in the IPO kitchen?**Golden Metal Resources Plc (PR
Small Cap Feast - Allergy Therapeutics, Belvoir Group, Coro Energy, and more...
27 March 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**LON:BCE, intends to join the AIM
Allergy Therapeutics to suspend shares after accounts delay
"Shares of the company will be suspended from trading from 7.30 am on 3 January 2023"
Allergy Therapeutics plans for UK manufacturing site restart is "welcome news" says finnCap
The finnCap analysts said: "While its competitors will no doubt take advantage of this hiatus, we think it will be a FY 2023 event only and, to that extent, leave FY 2024 forecasts unchanged"
Allergy Therapeutics to resume UK production in mid-November
AIM-quoted biotech company voluntarily paused production following an internal review
Allergy Therapeutics CEO: Temporary production pause will help build capacity for future growth
"This temporary pausing of production is a necessary step to ensure that we can both continue to deliver the highest standards of quality in our products and build capacity for the future growth of the group,” said chief executive Manuel Ll
Allergy Therapeutics raises funds as it gears up for the start of two key clinical trials
The fund raising is supported by a number of the company's largest shareholders and the proceeds will help fund the group's Phase I peanut trial and Grass Phase III trial
Allergy Therapeutics looks ahead to start of clinical trials
The hay fever and vaccine specialist said revenues for the year to June 2022 will be £72.8mln
Allergy Therapeutics to present 18 posters at EAACI conference
“Our latest findings pave the way for the initiation of two key clinical trials later this year," said chief executive Manuel Llobet
Allergy Therapeutics says CFO to leave
Nick Wykeman will depart in six months after six successful years with the business
Allergy Therapeutics to present new data on lead vaccines this week
Data from its grass pollen jab field study showed clinically relevant and statistically significant reductions in daily symptoms
Allergy Therapeutics primed for a pivotal year
Our company continues to stand out as a high-value hybrid, with its strong commercial business and high science R&D programmes," said chief executive Manuel Llobet
Allergy Therapeutics posts improved results from hay fever study
An improvement in symptoms of 39.5% was recorded gainst 36.8% previously